11,100 Shares in DaVita Inc. (NYSE:DVA) Bought by Caisse DE Depot ET Placement DU Quebec

Caisse DE Depot ET Placement DU Quebec purchased a new position in shares of DaVita Inc. (NYSE:DVA - Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 11,100 shares of the company's stock, valued at approximately $1,820,000.

Several other large investors also recently made changes to their positions in the stock. PDT Partners LLC raised its holdings in DaVita by 25.8% in the 3rd quarter. PDT Partners LLC now owns 26,887 shares of the company's stock valued at $4,408,000 after acquiring an additional 5,506 shares in the last quarter. Verition Fund Management LLC raised its holdings in DaVita by 313.6% in the 3rd quarter. Verition Fund Management LLC now owns 9,603 shares of the company's stock valued at $1,574,000 after acquiring an additional 7,281 shares in the last quarter. Captrust Financial Advisors raised its holdings in DaVita by 16.6% in the 3rd quarter. Captrust Financial Advisors now owns 3,992 shares of the company's stock valued at $654,000 after acquiring an additional 569 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in DaVita by 22.3% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 114,166 shares of the company's stock valued at $18,715,000 after acquiring an additional 20,782 shares in the last quarter. Finally, CreativeOne Wealth LLC raised its holdings in DaVita by 12.3% in the 3rd quarter. CreativeOne Wealth LLC now owns 3,314 shares of the company's stock valued at $543,000 after acquiring an additional 363 shares in the last quarter. Institutional investors own 90.12% of the company's stock.

DaVita Price Performance

NYSE DVA traded down $0.62 during trading hours on Wednesday, reaching $163.39. 413,823 shares of the company's stock were exchanged, compared to its average volume of 817,515. The stock has a market cap of $13.40 billion, a PE ratio of 17.69, a price-to-earnings-growth ratio of 0.92 and a beta of 0.90. DaVita Inc. has a one year low of $103.40 and a one year high of $169.51. The firm has a fifty day moving average of $158.66 and a 200-day moving average of $149.84. The company has a current ratio of 1.37, a quick ratio of 1.33 and a debt-to-equity ratio of 15.78.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing analysts' consensus estimates of $2.76 by ($0.17). The firm had revenue of $3.26 billion during the quarter, compared to the consensus estimate of $3.25 billion. DaVita had a net margin of 6.53% and a return on equity of 88.18%. The firm's quarterly revenue was up 4.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.85 earnings per share. On average, equities research analysts predict that DaVita Inc. will post 9.71 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Bank of America increased their target price on DaVita from $139.00 to $145.00 and gave the stock an "underperform" rating in a report on Wednesday, August 7th. Barclays increased their target price on DaVita from $150.00 to $164.00 and gave the stock an "equal weight" rating in a report on Thursday, October 31st. Truist Financial increased their target price on DaVita from $165.00 to $175.00 and gave the stock a "hold" rating in a report on Monday, October 7th. Finally, UBS Group increased their target price on DaVita from $169.00 to $175.00 and gave the stock a "buy" rating in a report on Thursday, August 8th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat.com, DaVita currently has a consensus rating of "Hold" and an average price target of $161.80.

Insider Buying and Selling at DaVita

In other news, CEO Javier Rodriguez sold 50,000 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $165.05, for a total value of $8,252,500.00. Following the transaction, the chief executive officer now owns 837,835 shares of the company's stock, valued at $138,284,666.75. This represents a 5.63 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 2.00% of the company's stock.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.